2012 was an exciting year for the Abramson Cancer Center. We are featuring blogs featured on the Focus On Cancer blog that highlight cancer treatment breakthroughs, coping tips and ideas, education and inspiration. Today, we are highlighting the partnership between the Stand Up 2 Cancer Foundation and Penn Medicine.
About Stand Up 2 Cancer
Founded in 2008, SU2C has raised more than $180 million for innovative cancer research. Since its inception, SU2C has made grants to seven multi-disciplinary “Dream Teams” of researchers as well as to 26 young innovative scientists who are undertaking potentially high-reward projects to end the reign of cancer as a leading cause of death in the world today.Eighty-five institutions are currently involved, including Penn Medicine’s Abramson Cancer Center.
The Penn Medicine SU2C Dream Team
As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer. More than 90 percent of patients die within the first year of diagnosis. Recent advancements have had little impact, and a new approach is desperately needed.
Members of the Pancreatic Cancer SU2C Dream Team at Penn Medicine
Pancreatic cancer researchers at Penn Medicine are at the forefront of developing new, personalized approaches to pancreatic cancer treatment.These Penn clinicians and researchers are part of the SU2C Pancreatic Cancer Dream Team.
Chi Van Dang, MD, PhD
Professor of Medicine, Hematology/Oncology
Director, Abramson Cancer Center
Director, Abramson Family Cancer Research Institute
Jeffrey A. Drebin, MD, PhD, FACS
John Rhea Barton Professor of Surgery
Chairman, Department of Surgery
Hank Kung, PhD
Professor of Radiology and Pharmacology
Department of Radiology
Perelman School of Medicine
Peter J. O’Dwyer, MBBCh, MD
Professor of Medicine, Hematology/Oncology
Perelman School of Medicine
